hs-CRP Biomarker in Breast Cancer
Regular monitoring of hs-CRP holds promise as a biomarker for identifying women with early-stage breast cancer at low risk for asymptomatic trastuzumab-induced cardiotoxicity. Easily obtainable biomarker with rapid results for evaluating cardiotoxicity related to trastuzumab therapy.











